Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670053 | 0.82 | AOC3 (0.44) | ALDH1A1KDM4EL3MBTL1ADRB3LMNA | |
| SCHEMBL2086312 | 0.82 | KDM4E (0.45) | ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL4542370 | 0.81 | LMNA (0.45) | ALDH1A1KDM4EL3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL4542365 | 0.81 | LMNA (0.45) | ALDH1A1KDM4EL3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL4614360 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EL3MBTL1CYP3A4ADRB3 | |
| SCHEMBL5727824 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EL3MBTL1CYP3A4ADRB3 | |
| SCHEMBL4239577 | 0.79 | KDM4E (0.36) | ALDH1A1KDM4EL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL4239581 | 0.79 | KDM4E (0.36) | ALDH1A1KDM4EL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL1841051 | 0.78 | KDM4E (0.38) | ALDH1A1KDM4EL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL1843192 | 0.78 | KDM4E (0.38) | ALDH1A1KDM4EL3MBTL1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-7576081-B2 | Central nervous system disorders ; sexual disorders; hypotensive agents; analgesics; neurodegenerative disease; obesity; Alzheimer's disease; obsessive compulsive disorders; antidepressants | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060235016-A1 | Morpholine Dopamine Agonists | PFIZER INC | 2006-10-19 | — | — | US | disclosed |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | VAN DER GRAAF PIETER H | 2006-03-09 | — | — | US | disclosed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235016-A1 | Morpholine Dopamine Agonists | DBH, OPRM1, ADRA2B | ALDH1A1 1143/4885KDM4E 3956/4885L3MBTL1 2152/4885 |
| US-20040259874-A1 | Morpholine dopamine agonists | DBH, OPRM1, OPRD1 | ALDH1A1 957/4885KDM4E 4218/4885L3MBTL1 2418/4885 |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | DBH, OPRM1, CHRM1 | ALDH1A1 1146/4885KDM4E 3890/4885L3MBTL1 2207/4885 |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRD1, OPRK1 | ALDH1A1 528/4885KDM4E 3456/4885L3MBTL1 335/4885 |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | DRD3, ADRB3, DRD2 | ALDH1A1 2526/4885KDM4E 4333/4885L3MBTL1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.